By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc. have jointly announced positive results from a Phase II weight loss study for HRS9531, a GLP-1/GIP receptor dual agonist. The study evaluated the drug at an 8 mg dose, which achieved significant weight loss and demonstrated a good safety and tolerability profile. Detailed efficacy and safety data will be presented at an upcoming academic meeting.
HRS9531: Development and Licensing
HRS9531 is currently undergoing Phase III studies for the treatment of obesity and type 2 diabetes. The drug was licensed to Kailera in a USD 6 billion deal for exclusive development, manufacturing, and commercialization rights globally, excluding Greater China. This transaction also included a 19.9% stake in Kailera by Hengrui, highlighting the strategic importance of the partnership.
Previous Study Results
Previously, Hengrui Pharma presented results at the American Diabetes Association (ADA) Scientific Sessions in June 2024. The data showed that HRS9531 was well-tolerated and demonstrated dose-dependent, placebo-adjusted mean weight loss across four doses administered weekly by subcutaneous injection. The maximum placebo-adjusted mean weight loss was 16.7% (p<0.0001) at the 6 mg dose at 24 weeks, indicating the drug’s potential as a significant treatment option for weight management and diabetes.-Fineline Info & Tech